Today it is frequently utilised as a differentiation marker for non-epithelial and epithelial derived neoplasms and it has also been identified as a potential targed for cancer therapies since appropriate anti-EpCAM-antibodies (e.g. Adecatumumab and Catumaxomab) are available32, 42. This evidence concerns the gene EPCAM and neoplasm.